Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine

Figures & data

Figure 1. rSBA or hSBA GMTs pre-vaccination, one-month post-primary vaccination, pre-booster and one-month post-booster vaccination.

Geometric mean titers (GMT) (95% CI), hSBA serum bactericidal antibody generated with human complement, rSBA serum bactericidal antibody generated with rabbit complement. The percentage of infants with titers ≥8 are shown as the numbers above the graph. Adapted from Merino Arribas et al. [30].

Figure 2. hSBA meningococcal serogroup GMT (95% CI) in children pre-vaccination and at 5, 12 and 13 months of age.

GMT = geometric mean titer; hSBA = serum bactericidal antibody generated with human complement. The percentage of infants with titers ≥4 are shown as the numbers above the graph. Adapted from Perrett et al. [31].

Figure 3. rSBA GMT at year 3, 4, post-booster and year 5, and hSBA GMT at pre-vaccination, one-month post-vaccination, year 2, 3, 4, post-booster and year 5.

GMT = Geometric Mean Titers, hSBA = serum bactericidal antibody generated with human complement, rSBA = serum bactericidal antibody generated with rabbit complement. The percentage of infants with rSBA titers ≥8 or hSBA titers ≥4 are shown as the numbers above the graph. Adapted from Vesikari et al. [29].

Figure 4. rSBA GMT at 1-month (M1), 32-months (M32), 44-months (M44), 56-months (M56) and 68-months (M68) post-primary vaccination, and 1-month pre- and post-booster; as well as hSBA GMT at 32-months (M32), 44-months (M44), 56-months (M56) and 68 months (M68) post-primary vaccination.

GMT = Geometric Mean Titers, hSBA = serum bactericidal antibody generated with human complement, rSBA = serum bactericidal antibody generated with rabbit complement. The percentage of infants with rSBA titers ≥8 or hSBA titers ≥4 are shown as the numbers above the graph. Adapted from Knuf et al. [32,33].

Figure 5. hSBA GMTs at baseline (Day 1) and post-MenACWY-CRM₁₉₇ (Day 29).

GMT = Geometric Mean Titer, hSBA = Serum Bactericidal Antibody generated with human complement. The percentage of infants with hSBA titers ≥8 are shown as the numbers above the graph. Adapted from Huang et al. [34].

Figure 6. rSBA GMT at baseline, 1-month post-vaccination and 2-years post-vaccination.

GMT Geometric Mean Titers, rSBA serum bactericidal antibody generated with rabbit complement. The percentage of infants with rSBA titers ≥8 are shown as the numbers above the graph. Adapted from Quiambao et al. [35].

Figure 7. rSBA and hSBA GMT at 1-month post- and 22-months post-vaccination.

GMT = Geometric Mean Titers, hSBA = Serum Bactericidal Antibody generated with human complement, rSBA = serum bactericidal antibody generated with rabbit complement. The percentage of infants with rSBA and hSBA titers ≥8 are shown as the numbers above the graph. Adapted from Gill et al. [36].

Merino Arribas JM, Carmona Martínez A, Horn M, et al. Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants. Pediatr Infect Dis J. 2017;36(4):e98–e107.

 PubMed Web of Science ®Google Scholar

Perrett K, Snape M, Ford K, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J. 2009;28(3):186–193.

 PubMed Web of Science ®Google Scholar

Vesikari T, Forsten A, Bianco V, et al. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2015;12(1):132–139.

 Web of Science ®Google Scholar

Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr. 2013;12(5):601–612.

 Web of Science ®Google Scholar

Knuf M, Helm K, Kolhe D, et al. Antibody persistence and booster response 68 months after vaccination at 2–10 years of age with one dose of MenACWY-TT conjugate vaccine. Vaccine. 2018;36(23):3286–3295.

 PubMed Web of Science ®Google Scholar

Huang L, Chiu N, Yeh S, et al. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2–18 years in Taiwan: results of an open label study. Vaccine. 2014;32(40):5177–5184.

 PubMed Web of Science ®Google Scholar

Quiambao B, Jain H, Bavdekar A, et al. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. Hum Vaccin Immunother. 2016;12(8):2162–2168.

 PubMed Web of Science ®Google Scholar

Gill C, Baxter R, Anemona A, et al. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin. 2010;6(11):881–887.

 PubMed Web of Science ®Google Scholar